Pancreatic Cancer Research

ResearcherUniversity of OuluNo recent work listed

Joni Leppänen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6360-021X; OpenAlex author ID A5090395060. Sources: OpenAlex.

Their work

Papers
5 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
10
Papers, trials and grants by year

2017: 1 paper · 2018: 2 papers · 2019: 2 papers

Papers 5

  1. Immune cell score in pancreatic cancer-comparison of hotspot and whole-section techniques. First author DOI 10.1007/s00428-019-02549-1↗
  2. Tenascin C, Fibronectin, and Tumor-Stroma Ratio in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001195↗
  3. Proteins of the retinoblastoma pathway, FEN1 and MGMT are novel potential prognostic biomarkers in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.prp.2018.04.016↗
  4. Weak HIF-1alpha expression indicates poor prognosis in resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12957-018-1432-4↗
  5. High toll-like receptor (TLR) 9 expression is associated with better prognosis in surgically treated pancreatic cancer patients. Co-author DOI 10.1007/s00428-017-2087-1↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kirsi‐Maria Haapasaari · 5 shared papers, 2017–2019 · strength 0.44
  2. Joel Isohookana · 4 shared papers, 2017–2019 · strength 0.34
  3. Tuomo J. Karttunen · 4 shared papers, 2017–2019 · strength 0.33
  4. Joonas H. Kauppila · 3 shared papers, 2017–2019 · strength 0.24
  5. Heikki I. Huhta · 3 shared papers, 2017–2019 · strength 0.24
  6. Peeter Karihtala · 2 shared papers, 2018–2019 · strength 0.19
  7. Ylermi Soini · 1 shared paper, 2018 · strength 0.11
  8. Ilmo Kellokumpu · 1 shared paper, 2019 · strength 0.10
  9. Jan Böhm · 1 shared paper, 2019 · strength 0.10
  10. Kyösti Tahkola · 1 shared paper, 2019 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.